Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by US Bancorp DE

US Bancorp DE decreased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 15.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,270 shares of the company’s stock after selling 610 shares during the quarter. US Bancorp DE’s holdings in Prestige Consumer Healthcare were worth $281,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $84,932,000. BNP Paribas Financial Markets raised its holdings in Prestige Consumer Healthcare by 1,073.3% in the 4th quarter. BNP Paribas Financial Markets now owns 203,903 shares of the company’s stock valued at $15,923,000 after buying an additional 186,524 shares during the period. GAMMA Investing LLC raised its holdings in Prestige Consumer Healthcare by 11,580.3% in the 1st quarter. GAMMA Investing LLC now owns 161,538 shares of the company’s stock valued at $13,887,000 after buying an additional 160,155 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $7,778,000. Finally, Envestnet Asset Management Inc. raised its holdings in Prestige Consumer Healthcare by 124.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 169,926 shares of the company’s stock valued at $13,270,000 after buying an additional 94,192 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Down 2.8%

Shares of NYSE:PBH opened at $64.60 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The firm has a market capitalization of $3.18 billion, a PE ratio of 15.16, a price-to-earnings-growth ratio of 2.10 and a beta of 0.43. The firm’s 50-day moving average is $77.67 and its two-hundred day moving average is $81.68. Prestige Consumer Healthcare Inc. has a 1 year low of $62.95 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%. The firm had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. During the same quarter in the previous year, the company posted $0.90 earnings per share. The firm’s quarterly revenue was down 6.6% on a year-over-year basis. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on PBH shares. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Wall Street Zen lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Royal Bank Of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.